Navigation Links
SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Date:11/1/2007

SAN DIEGO and MCLEAN, Va., Nov. 1 /PRNewswire-FirstCall/ -- Science Applications International Corporation (NYSE: SAI) today announced that it was awarded a contract extension by the National Institute of Allergy and Infectious Diseases' (NIAID) Division of Microbiology and Infectious Diseases (DMID), part of the National Institutes of Health, to provide malaria vaccine production and support services.

The seven-year cost-plus-fixed-fee contract has an estimated value of $32.7 million. The contract extension represents a follow-on effort for previous work SAIC has been performing for NIAID since 2000.

The SAIC-led team will deliver research and development services to support process development and pilot lot production of promising malaria vaccine candidates into products suitable for evaluation in human clinical studies. SAIC will serve as the project management arm for these activities, helping to identify optimal production and purification strategies for clinical-grade malaria immunogens, performing pilot lot production, formulation, preclinical testing, and providing nonclinical development support for promising vaccine candidates. SAIC will also provide regulatory support for investigational new drug applications.

"SAIC is honored that NIAID has selected us to continue to support the development and characterization of malaria vaccine candidates," said Robert McCord, SAIC business unit general manager. "Our life sciences team is dedicated to the search for a viable vaccine for this disease, which kills more than one million infants, young children and pregnant women every year."

SAIC is a leading provider of scientific, engineering, systems integration and technical services and solutions to all branches of the U.S. military, agencies of the Department of Defense, the intelligence community, the U.S. Department of Homeland Security and other U.S. Government civil agencies, as well as to customers in selected commercial markets. With more than 44,000 employees in over 150 cities worldwide, SAIC engineers and scientists solve complex technical challenges requiring innovative solutions for customers' mission-critical functions. SAIC had annual revenues of $8.3 billion for its fiscal year ended January 31, 2007.

SAIC: FROM SCIENCE TO SOLUTIONS(R)

Statements in this announcement other than historical data and information constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements or industry results to be very different from the results, performance or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2007, and such other filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

Contact: Melissa Koskovich, McLean Ron Zollars, San Diego

703/676-6762 858/826-7896

koskovichm@saic.com zollarsr@saic.com


'/>"/>
SOURCE SAIC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
2. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
5. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
6. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
7. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
10. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
11. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals ... company, announced today that it has filed a patent ... and other cancers. --> ... cancer by administration of Ceplene (histamine dihydrochloride) in combination ... methods of predicting the efficacy of Ceplene and IL-2 ...
(Date:2/10/2016)... Feb. 10, 2016  The ALS Association, in partnership with ... Challenge to generate a biomarker to track TDP43 aggregation. The ... to a $1 million investment. --> ... that affects nerve cells in the brain and the spinal ... and control muscle movement, which often leads to total paralysis ...
(Date:2/10/2016)... MOUNTAIN VIEW, Calif. , Feb. 10, ... result of a synergistic confluence of various ... unique value propositions, previously unavailable. These opportunities ... convergence and convergence, in turn, drives the ... Today,s entrepreneurial scenario is characterized by technology ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... 32224, February 26th: Amateur & Professional Divisions - Time: 7:00pm – 10:00pm ... 10:00pm | Ticket Prices $30, Social Media: http://www.USPoleSportsFed.org , Facebook: ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of ... to being an internationally recognized leader in their industry. , "We are very proud ... President of Workrite. “Workrite recognized the importance of good ergonomics before most of ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... and staff helped give free oral screenings to 150 children in kindergarten through ... , The College of Dental Medicine joined Chinese American Dental Society of Southern ...
Breaking Medicine News(10 mins):